Histology
Clear Cell Adenocarcinoma
CI-CAN-00002377Explore in graph →
150 active trials2 approved drugs19 evidence items
Loading cancer entity…
Histology
CI-CAN-00002377Explore in graph →
Clinical trials
362 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (53)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02446600 | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 3 | 579 | National Cancer Institute (NCI)NIH | 4 | Sep 29, 2026 | clinicaltrials |
| NCT02502266 | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer | active not recruiting | Phase 2 / Phase 3 | 582 | National Cancer Institute (NCI) |
| 5 |
| Sep 29, 2026 |
| clinicaltrials |
| NCT05256225 | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | recruiting | Phase 3 | 360 | National Cancer Institute (NCI)NIH | 3 | Sep 29, 2026 | clinicaltrials |
| NCT07011719 | Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma | recruiting | Phase 3 | 720 | Arcus Biosciences, Inc.INDUSTRY | 17 | Sep 29, 2026 | clinicaltrials |
| NCT04810078 | A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread(CheckMate-67T) | active not recruiting | Phase 3 | 681 | Bristol-Myers SquibbINDUSTRY | 17 | Sep 22, 2026 | clinicaltrials |
| NCT04575935 | Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial | recruiting | Phase 3 | 580 | M.D. Anderson Cancer CenterOTHER | 5 | Sep 14, 2026 | clinicaltrials |
| NCT06661720 | Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer(STRIKE) | recruiting | Phase 3 | 1,040 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03793166 | Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | active not recruiting | Phase 3 | 1,175 | National Cancer Institute (NCI)NIH | 2 | Aug 31, 2026 | clinicaltrials |
| NCT02839707 | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 / Phase 3 | 444 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 | clinicaltrials |
| NCT01575548 | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery | active not recruiting | Phase 3 | 129 | National Cancer Institute (NCI)NIH | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03914612 | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | active not recruiting | Phase 3 | 813 | National Cancer Institute (NCI)NIH | 5 | Jul 31, 2026 | clinicaltrials |
| NCT00326898 | Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery(ASSURE) | completed | Phase 3 | 1,943 | National Cancer Institute (NCI)NIH | 3 | Jun 23, 2026 | clinicaltrials |
| NCT07383441 | Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | recruiting | Phase 3 | 718 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 11, 2026 | clinicaltrials |
| NCT00951496 | Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 3 | 1,560 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07197580 | Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC(LUTEON) | recruiting | Phase 3 | 40 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT00565851 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 1,052 | National Cancer Institute (NCI)NIH | 3 | Dec 30, 2025 | clinicaltrials |
| NCT03422198 | Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer(SAVE) | recruiting | Phase 3 | 188 | University of UtahOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT07084909 | Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC(HARRIER) | withdrawn | Phase 2 / Phase 3 | 0 | Lantheus Medical ImagingINDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT04510597 | Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial(PROBE) | recruiting | Phase 3 | 364 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06750419 | 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study | recruiting | Phase 3 | 82 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04227522 | Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients(MAMOC) | completed | Phase 3 | 42 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT02501954 | Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol | completed | Phase 3 | 48 | Women's Cancer Care Associates, LLCOTHER | 2 | Jul 23, 2024 | clinicaltrials |
| NCT03849118 | 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study(89ZR-TLX250) | completed | Phase 3 | 300 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 8 | May 17, 2024 | clinicaltrials |
| NCT00942357 | Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer | unknown | Phase 3 | 813 | Gynecologic Oncology GroupNETWORK | 3 | Oct 19, 2021 | clinicaltrials |
| NCT00108745 | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer | unknown | Phase 3 | 1,157 | GOG FoundationNETWORK | 1 | Sep 30, 2021 | clinicaltrials |
| NCT02065687 | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | unknown | Phase 2 / Phase 3 | 469 | Gynecologic Oncology GroupNETWORK | 1 | Sep 30, 2021 | clinicaltrials |
| NCT00262847 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 3 | 1,873 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT00807768 | Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer | unknown | Phase 3 | 601 | Gynecologic Oncology GroupNETWORK | 2 | Mar 20, 2019 | clinicaltrials |
| NCT01198158 | Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy | terminated | Phase 3 | 77 | National Cancer Institute (NCI)NIH | 1 | Mar 6, 2019 | clinicaltrials |
| NCT00719303 | Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | unknown | Phase 3 | 1,070 | Gynecologic Oncology GroupNETWORK | 1 | Feb 19, 2018 | clinicaltrials |
| NCT00006011 | Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer | completed | Phase 3 | 659 | Gynecologic Oncology GroupNETWORK | 1 | May 19, 2015 | clinicaltrials |
| NCT01492920 | Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy | withdrawn | Phase 3 | 0 | Gynecologic Oncology GroupNETWORK | 0 | Dec 31, 2014 | clinicaltrials |
Data updated 8 hours agoSource updated Sep 29, 2026source: clinicaltrials